Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2024 Jul 14;45(7):629-636.
doi: 10.3760/cma.j.cn121090-20240528-00194.

[Chinese consensus for the bispecific T cell engager in the treatment of acute lymphoblastic leukemia (2024)]

[Article in Chinese]
Union for China Leukemia of Chinese Society of Clinical Oncology; Union for Lymphoma Investigators of Chinese Society of Clinical Oncology; Chinese Society of Hematology, Chinese Medical Association; Chinese Hematology Association, Chinese Medical Doctor Association
Practice Guideline

[Chinese consensus for the bispecific T cell engager in the treatment of acute lymphoblastic leukemia (2024)]

[Article in Chinese]
Union for China Leukemia of Chinese Society of Clinical Oncology et al. Zhonghua Xue Ye Xue Za Zhi. .

Abstract
in English, Chinese

Acute lymphoblastic leukemia (ALL) is one of the most common acute leukemias, with rapid onset and progression. The standardized application of chemotherapy and transplantation have improved the prognosis of patients, while the unmet therapeutic needs still exist. Recently novel immunotherapies including Bispecific T cell Engager develop rapidly, offering more options for ALL treatment and also demanding higher requirements for clinical diagnosis and treatment management. Based on the evidence of domestic and international medical evidence and clinical experience, the expert panel updated Chinese consensus for the Bispeific T cell Engager in the treatment of B-cell acute lymphoblastic leukemia (2022) and formulated this edition of the Chinese expert consensus.

急性淋巴细胞白血病（acute lymphoblastic leukemia, ALL）是最常见的急性白血病之一，发病急、进展快，化疗和移植的规范化应用已极大改善患者预后，但仍存在未满足的治疗需求。近年以双特异性T细胞衔接器（Bispecific T cell Engager，BiTE）为代表的免疫治疗发展迅速，为ALL治疗提供了更多选择，同时也对临床诊疗管理提出了更高的要求。专家组基于国内外最新循证医学证据、相关指南和临床实践，对2022年版《双特异性T细胞衔接器治疗急性淋巴细胞白血病指导原则》进行更新，制定了该版中国专家共识。.

Keywords: Bispecific T cell engager; Immunotherapies; Leukemia, lymphoblastic, acute.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Hu Y, Zhang X, Zhang A, et al. Global burden and attributable risk factors of acute lymphoblastic leukemia in 204 countries and territories in 1990-2019: Estimation based on Global Burden of Disease Study 2019[J] Hematol Oncol. 2022;40(1):92–104. doi: 10.1002/hon.2936. - DOI - PubMed
    1. Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia[J] N Engl J Med. 2017;376(9):836–847. doi: 10.1056/NEJMoa1609783. - DOI - PMC - PubMed
    1. Wolf E, Hofmeister R, Kufer P, et al. BiTEs: bispecific antibody constructs with unique anti-tumor activity[J] Drug Discov Today. 2005;10(18):1237–1244. doi: 10.1016/S1359-6446(05)03554-3. - DOI - PubMed
    1. FDA granted accelerated approval to blinatumomab (Blincyto, Amgen Inc.) for the treatment of adult and pediatric patients with B-cell precursor acute lymphoblastic leukemia[EB/OL] https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grant... .
    1. 中国临床肿瘤学会白血病专家委员会, 中国临床肿瘤学会淋巴瘤专家委员会, 中华医学会血液学分会. 双特异性T细胞衔接器治疗急性淋巴细胞白血病指导原则(2022年版)[J] 中华血液学杂志. 2022;43(6):448–455. doi: 10.3760/cma.j.issn.0253-2727.2022.06.002. - DOI
    2. Union for China Leukemia & Lymphoma Investigators of Chinese Society of Clinical Oncology, Chinese Society of Hematology, Chinese Medical Association. Chinese consensus for the bispeific T cell engager in the treatment of B-cell acute lymphoblastic leukemia (2022)[J] Chin J Hematol. 2022;43(6):448–455. doi: 10.3760/cma.j.issn.0253-2727.2022.06.002. - DOI - PMC - PubMed

MeSH terms

Substances